Understanding Angelman Clinical Trials 101
Let's dive into the details surrounding Angelman Clinical Trials 101. It's an exciting time in
Key Takeaways about Angelman Clinical Trials 101
- Becky Burdine, PhD.
- For more information on spasticity or #YaleMedicine, visit: https://www.yalemedicine.org/conditions/
- Becky Crean, Ph.D., provides an update on the
- Becky Burdine discusses the genetics underlying different types of
- Angelman
Detailed Analysis of Angelman Clinical Trials 101
The second webinar update from Dr Amit Rakhit from Ovid Therapeutics with Paula Evans from the Foundation for I AM ALS' Mathews Adera, MD, Vice President, Neurodevelopment at Ovid Therapeutics discusses his company's
Clinicians from the ASF & Dup15q Alliance funded 15q Clinical Network discuss
That wraps up our extensive overview of Angelman Clinical Trials 101.
